Media coverage about Qiagen N.V. (NASDAQ:QGEN) has trended somewhat positive on Friday, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Qiagen N.V. earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.6465198704452 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern’s scoring:
- Qiagen Trying To Close In On Key Technical Benchmark (finance.yahoo.com)
- Reviewing Qiagen N.V. (QGEN) & Celyad SA (CYAD) (americanbankingnews.com)
- Investors watching summary on QIAGEN NV (QGEN) – Wall Street Morning (wallstreetmorning.com)
- QIAGEN NV (QGEN) has a value of $35.04 per share While UDR, Inc. (UDR) is stand at $38.36 – Stocks Gallery (stocksgallery.com)
- QIAGEN NV (QGEN) – Traders Alert on Unusual Volume Activity – Wall Street Morning (wallstreetmorning.com)
Several analysts have recently issued reports on QGEN shares. Commerzbank Ag restated a “buy” rating on shares of Qiagen N.V. in a research report on Friday, June 23rd. BidaskClub cut shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Morgan Stanley restated an “overweight” rating and set a $37.00 target price (up from $36.00) on shares of Qiagen N.V. in a research report on Monday, July 10th. Zacks Investment Research upgraded shares of Qiagen N.V. from a “sell” rating to a “hold” rating and set a $38.00 target price on the stock in a research report on Wednesday, July 12th. Finally, Wells Fargo & Company restated a “market perform” rating and set a $31.00 target price (up from $28.00) on shares of Qiagen N.V. in a research report on Thursday, July 13th. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Qiagen N.V. presently has an average rating of “Hold” and a consensus price target of $33.28.
Qiagen N.V. (NASDAQ:QGEN) last issued its earnings results on Thursday, July 27th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.02. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The company had revenue of $349.00 million for the quarter, compared to the consensus estimate of $353.09 million. During the same period in the previous year, the firm earned $0.24 earnings per share. Qiagen N.V.’s quarterly revenue was up 4.4% compared to the same quarter last year.
TRADEMARK VIOLATION NOTICE: This news story was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.themarketsdaily.com/2017/10/13/qiagen-n-v-qgen-receives-daily-media-sentiment-score-of-0-17.html.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.